Suppression of angiotensin II formation by angiotensin-converting enzyme inhibitors or blockade of the angiotensin II receptor by angiotensin receptor blockers is a powerful therapeutic strategy to slow the progression of renal disease. However, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers provide only imperfect protection against the progression of chronic kidney disease to end-stage renal failure. Hence, innovative approaches are needed to keep patients with chronic kidney disease off dialysis. Angiotensin II activates at least two receptors, namely the angiotensin II type 1 (AT 1 ) and angiotensin II type 2 (AT 2 ) receptors. The majority of the effects of angiotensin II, such as vasoconstriction, inflammation, and matrix deposition, are mediated via the AT 1 receptor. It is thought that the AT 2 receptor counteracts these effects and plays a role in nephroprotection. However, recent data support the notion that the AT 2 receptor transduces pro-inflammatory effects and promotes fibrosis and hypertrophy. Therefore, the question of whether stimulation of the AT 2 receptor could represent a silver bullet for the treatment of chronic kidney disease or may, on the contrary, exert detrimental effects on renal physiology remains unresolved. Recent data from AT 2 receptor-knockout mice demonstrate that the loss of AT 2 receptor signalling is associated with increased renal injury and mortality in chronic kidney disease. This raises the expectation that pharmacological stimulation of the AT 2 receptor may positively influence renal pathologies. However, further research is needed to explore the question whether AT 2 receptor stimulation may represent a new therapeutic strategy for the treatment of chronic kidney disease.
Introduction
Chronic kidney disease has become an increasingly burdensome health problem. For instance, results from the third National Health and Nutrition Examination Survey indicate that 3% of the US adult population suffer from chronic renal failure, as evidenced by elevated serum creatinine values. 1 The prevalence of end-stage renal disease is rising at an alarming rate, and the increasing number of patients with end-stage renal disease is one of the major challenges in today's nephrology practices worldwide. 2 Hypertension and proteinuria are the most important risk factors for the progression of renal disease. Haemodynamic and non-haemodynamic effects of angiotensin II are critically involved in the development and maintenance of hypertension and proteinuria. Therefore, suppression of angiotensin II formation by angiotensin-converting enzyme (ACE) inhibitors and blockade of the angiotensin II type 1 (AT 1 ) receptor by angiotensin II receptor blockers (ARB) are powerful therapeutic strategies that effectively slow the progression of renal disease by lowering blood pressure and proteinuria. 3 It has been speculated that the angiotensin II type 2 (AT 2 ) receptor contributes to the beneficial effects of ARBs because AT 1 receptor blockade leads to an increased synthesis of angiotensin II, which in turn stimulates the unopposed AT 2 receptor.
General properties of the AT 1 and AT 2 receptors
Almost all classical angiotensin II-induced functions, such as vasoconstriction, aldosterone release, stimulation of tubular sodium transport, pro-inflammatory effects, as well as profibrogenic and growth-stimulatory actions, are mediated by the AT 1 receptor. Experimental and clinical studies investigating the effect of ARBs and studies in AT 1a receptor-knockout mice indicate an involvement of the AT 1 receptor in the progression of chronic kidney disease. 3 The function of the AT 2 receptor is less clear, but it has been proposed that activation of this receptor antagonises AT 1 receptor-mediated effects, thereby providing negative feedback control. 4 In line with this notion, activation of the AT 2 receptor has been shown to decrease blood pressure, 5 These actions appear to be mediated via G-protein-dependent and -independent activation of serine/threonine as well as tyrosine phosphatases, and may involve reduced phosphorylation and hence activation status of key signalling elements of survival and growth pathways, such as Akt/PKB and ERK1/2. 6, 7 However, the impact of the AT 2 receptor on the process of cell growth and inflammation is still controversially discussed, as several groups have postulated a role for the receptor in the development of cardiac hypertrophy. In addition, AT 2 receptormediated induction of NFkappaB and chemokine expression such as RANTES has been reported in rat glomerular endothelial cells. 8, 9 Role of the AT 2 receptor in renal development and physiology As described for several species including humans, the AT 2 receptor is highly expressed in foetal and neonatal kidneys, but expression levels rapidly decline during adolescence. 10, 11 In the foetal human kidney, AT 2 receptors are expressed in the undifferentiated mesenchyme of the mesonephros and, at later gestational stages, also in the surrounding tubules and immature glomeruli. 11 The expression pattern indicates an important role for the receptor in renal cell differentiation and maturation. Other authors suggested an increased incidence of congenital anomalies of the kidney and the urinary tract (CAKUT syndrome) in AT 2 receptor-knockout mice. 12 However, AT 2 receptor-knockout mice of the FVB/N strain show normal kidney and urinary tract development. In the kidney of human adults, AT 2 receptors are detectable in renal resistance vessels, tubules, and to a slight extent in glomerular cells. It has also been suggested that the physiological AT 2 receptor function may participate in renal sodium and water excretion and influence renal blood flow via induction of renal nitric oxide and consecutive cGMP production. 13, 14 In this context, it is interesting to note that genetic variations of the AT 2 receptor were found to influence renal function in humans with diabetic nephropathy. 15 Role of the AT 2 receptor in chronic kidney disease Astonishingly, there are only a few experimental studies on the role of the AT 2 receptor in the pathogenesis of chronic kidney disease. Data from studies on AT 2 receptor-deficient mice may, for example, yield essential information on the role of the receptor in renal pathophysiology.
However, most of the data on renal properties of the AT 2 receptor have been generated using AT 2 receptor antagonists such as PD123319, which, unfortunately, remain controversial. For instance, conflicting results have been published regarding the effect of AT 2 receptor antagonists in chronic kidney disease. The results range from worsening of renal function after treatment with PD123319, which suggests a beneficial effect of the AT 2 receptor, to no effect on, or improvement of, renal injury after treatment with the antagonist. Moreover, Siragy et al. found a worsening of renal function in the renal wrap model after PD123319 treatment. 14 Similarly, Vazquez and colleagues observed an increase in blood pressure and renal injury in the renal ablation model after treatment with the AT 2 receptor antagonist. 16 In contrast, Cao et al. demonstrated a beneficial effect of this compound in the same model. 17 In addition, Esteban et al. reported decreased inflammatory cell infiltration in the unilateral ureteral obstruction model after treatment with PD123319, 18 indicating pro-inflammatory characteristics of the AT 2 receptor. The results of studies using so-called antagonists have yet to be carefully evaluated. Dosing and timing of the antagonist may cause opposite effects. Due to a possible agonistic effect of PD123319 on the AT 1 receptor, it may not be possible to draw a definite conclusion on the functional importance of the AT 2 receptor in chronic kidney disease from these studies. In addition, PD123319 lacks specificity when applied at higher doses and has therefore produced contradictory findings, especially when given in vivo. In addition, interpretation of the PD123319 data mentioned above might be hampered by the effect of the AT 2 receptor antagonist on blood pressure. In conclusion, the role of the AT 2 receptor in the development and progression of chronic kidney disease still remains elusive.
Renal ablation to study the progression of chronic kidney disease The renal ablation model, achieved by unilateral nephrectomy and removal of two-thirds of the other kidney, has been extensively and successfully used to study the pathogenesis of renal injury in rats and the effectiveness of intervention strategies. 19 Mice, especially C57BL/6 mice, appear to be very resistant to renal injury models, such as angiotensin II infusion, protein overflow, or renal ablation. Therefore, scientists across the world may have encountered strain-specific difficulties when studying renal disease in genetically modified mice of this background. Since mice of the FVB/N strain are susceptible to kidney injury after renal ablation and develop renal Paper SAGE Publications 2010 Los Angeles, London, New Delhi and Singapore morbidity and mortality after 5/6 nephrectomy, we induced renal ablation in wild-type and AT 2 receptor-knockout mice of the FVB/N background and compared morbidity and mortality to study the role of the AT 2 receptor in chronic kidney disease. 20 Chronic kidney disease in AT 2 receptor-knockout mice After renal ablation, a higher mortality rate was observed in knockout mice compared to wildtype mice. Impairment of renal function, glomerular injury, and albuminuria were significantly higher in knockout mice than in wild-type mice. Renal injury was accompanied by increased expression of extracellular matrix proteins and enhanced inflammation in the knockout mice, as evidenced by augmented infiltration of monocytes/ macrophages and higher renal expression of chemokines. This finding is in line with recent data showing acceleration of renal injury in AT 2 receptor-knockout mice during unilateral ureteral obstruction. 21 The data are also supported by recently published findings that overexpression of the AT 2 receptor in vascular smooth muscle cells has protective effects in mice after renal ablation. 22 Why do AT 2 receptor-knockout mice develop more renal injury and more pronounced proteinuria than wild-type mice? Very recent data indicate an important role for the AT 2 receptor in the regulation of functional molecules of the slit diaphragm. 4 In this study, AT 2 receptor stimulation induced the expression of nephrin and podocin, two molecules that are critically important to podocyte integrity, in cultured podocytes in vitro and in a model of progressive proteinuria in vivo. Hence, AT 2 receptor deficiency in AT 2 receptor-knockout mice may impede important antiproteinuric mechanisms of the kidney.
As mentioned above, expression of AT 2 receptors is high in foetal and neonatal kidneys, but decreases during adolescence. 23 Therefore, the difference between knockout and wild-type mice may not only be caused by AT 2 receptor deficiency in the adult kidney, but may be in part also caused by discrete developmental differences making the animals more sensitive to damage. This problem is inherent in any knockout-based study. Although expression of the AT 2 receptor is low in the adult kidney, its expression is induced by proteinuria and in renal disease. 16, 24 This strongly suggests that overexpression of the AT 2 receptor might represent a counter-regulatory mechanism to the deleterious effects induced by angiotensin II-mediated stimulation of the AT 1 receptor in chronic kidney disease.
Role of the AT 2 receptor in the pharmacodynamic activity of ARBs Is there still room for research on the role of the AT 2 receptor in renal disease after ONTARGET? The ONTARGET trial demonstrated therapeutic equivalence between the ARB telmisartan and the ACE inhibitor ramipril with regard to the number of renal events or the number of patients reaching end-stage renal disease in a cohort of cardiovascular high-risk patients. 25 It is known that treatment with ARBs induces a spillover of angiotensin II to the AT 2 receptor, which, for example, is not the case in ACE inhibitor-treated patients. The pharmacodynamic relevance of AT 2 receptor stimulation for the clinical course of chronic kidney disease remains elusive in this context. However, the significance of a spillover of angiotensin II from the AT 1 receptor to the AT 2 receptor after administration of an ARB is quite low in the clinical setting. During physiological conditions, plasma concentrations of angiotensin II in humans have been described to be in the picomolar range, whereas treatment with ARBs roughly leads to a quadruplication of circulating angiotensin II levels. 26 However, angiotensin II plasma concentrations remain well below the Kd value of angiotensin II at the AT 2 receptor (approximately 5 nmol/L). Under these circumstances, angiotensin II-induced stimulation of the AT 2 receptor may therefore be insufficient to transduce the beneficial effects observed in experimental studies. It is therefore tempting to speculate that concomitant application of novel highpotency AT 2 receptor agonists and ARBs/ACE inhibitors may confer additional benefit in patients with chronic kidney disease. However, this speculation has yet to be proven, first in animal studies and later in patients with renal diseases.
Conclusion AT 2 receptor deficiency increases mortality and exacerbates renal injury in mice with chronic renal disease. Our data indicate that AT 2 receptor signalling exerts beneficial effects on chronic kidney disease. Aggravation of renal injury by AT 2 receptor deficiency suggests, but does not prove, that stimulation of the AT 2 receptor is nephroprotective. The only available AT 2 receptor partial agonist CGP42112 may exert both agonistic and antagonistic effects, depending on the activity of the renin-angiotensin system during a certain pathophysiological condition, thus rendering the interpretation of in vivo results rather difficult. The recent development of a selective nonpeptide AT 2 receptor agonist may help to answer this question. 27, 28 Our data clearly underline the importance of elucidating whether stimulation of the AT 2 receptor alone or in combination with blockers of the renin-angiotensin system has antiproteinuric, anti-inflammatory, and antifibrotic properties in chronic kidney disease (figure 1). If so, AT 2 receptor agonists may represent an innovative strategy for the treatment of chronic kidney disease and may help us to keep more patients off dialysis. The ultimate goal is to slow or, even better, to halt progression of chronic kidney disease. 
